
Replimune Group, Inc.
Replimune Group, Inc. (REPL)
WebsitePrice
Market cap
Next catalystExpected 2026TUDRIQEV / RP1 monotherapy — ARTACUS · Phase 1/2 dataSEC filing ↗
Cash
Chart & Events
Technology Summary
Scientific context
Detailed technology interpretation
Technology advantages
Clinical
Upcoming clinical milestones
Other pipelines
Approved / commercial
PreINDP1P2P3FilingApproved